FDA authorizes monoclonal antibody for treatment of COVID-19

The FINANCIAL —  The U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the investigational monoclonal antibody therapy bamlanivimab for the treatment of mild-to-moderate COVID-19 in adult and pediatric patients. Bamlanivimab is authorized for patients with positive results of direct SARS-CoV-2

More
7 mins read
1 3 4 5 6 7 30